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Abstract Metformin has been prescribed in pregnancy for
over 40 years; for much of this time, use has been limited both
in numbers and geographically, and the evidence base has
been confined to observational studies. In early years, per-
ceived safety concerns and lack of availability of the drug in
many countries acted as a barrier to use. More recently, RCTs
have begun to examine the role of metformin in pregnancy in
much-needed detail. However, this evidence base has been
interpreted differently in different countries, leading to very
wide variation in its current application in pregnancy. In this
short review, we will discuss the history of metformin in preg-
nancy and highlight some of the key clinical trials. We will
then consider some of the remaining controversies associated
with metformin use in pregnancy, most important of these
being the potential for long-term ‘programming’ effects on
the fetus as a result of metformin being able to cross the pla-
centa. We will also consider clinical situations where metfor-
min might be avoided. Finally, we will discuss some future
directions for this drug as it reaches its sixtieth anniversary.
Keywords Metformin . Pregnancy . Review . Teratogenesis
Abbreviations
AMPK AMP-activated protein kinase
ESC Embryonic stem cells
GDM Gestational diabetes
MATE Multidrug toxin and extrusion
MiG Metformin in Gestational Diabetes
mTOR Mechanistic target of rapamycin
OCT Organic cation transporter
PCOS Polycystic ovarian syndrome
Early use
The initial development and use of metformin (outside of
pregnancy) are reviewed elsewhere in this issue of
Diabetologia [1]. With regard to pregnancy, it is important
to note that it was acknowledged very early on that metformin
crossed the placenta. More recent studies show similar plasma
concentrations in the maternal and fetal circulation [2].
Further, the combination of increased lactic acidosis risk
(mainly observed with the metformin-related biguanide,
phenformin) and the relatively hypoxic fetal environment led
to important concerns regarding potential adverse effects of
metformin use in pregnancy, for both mother and child. In
fact, the safety concerns related to phenformin use resulted
in the withdrawal of metformin in many, although not all,
countries [3].
These early concerns are charted in influential reports of
the Aberdeen International Colloquia on Carbohydrate
Metabolism in Pregnancy and the Newborn. The first collo-
quium, reported in 1975, included an entire chapter on ‘the use
of sulphonylureas, biguanides and insulin in pregnancy’ [4].
By the time of the fourth report in 1988, the topic of use of
metformin was given only a few lines and it was noted that use
was not widespread [5].
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Metformin use did, however, continue in other parts
of the world. In developing countries, the relatively low
cost of metformin compared with insulin made it an
attractive option. Coetzee and colleagues published a
series of important observational papers, commencing
in the late 1970s, examining the use of metformin in
South Africa [6–8]. In South Africa and other countries,
where metformin was routinely used to treat type 2
diabetes, exposure inevitably began to occur in early
pregnancy leading to the separate analysis of safety in
early pregnancy, particularly regarding miscarriage and
congenital anomaly.
However, it was as metformin use became more popular in
polycystic ovarian syndrome (PCOS) that a more robust liter-
ature developed, investigating exposure of the fetus to metfor-
min in early pregnancy and, therefore, safety of its use.
Safety and efficacy of metformin during pregnancy
Safety in early pregnancy The early literature regarding
metformin use in early pregnancy in humans was based
on observational findings and of variable quality.
Studies were usually small and it was often difficult to
tease out the potential teratogenic effects of metformin,
particularly as opposed to the well-established effects of
maternal hyperglycaemia to increase risk of congenital
malformation [9]. Similarly, animal studies have not
been completely conclusive, and while increases in em-
bryonic AMP-activated protein kinase (AMPK; AMPK
activation being one potential effect of metformin) may
be key in diabetic embryopathy, animal studies have not
suggested an increase in embryopathy with early met-
formin exposure in vivo [10].
More recently, a meta-analysis based on metformin
exposure in 351 women with PCOS has been carried
out. Interestingly, the findings of this study do not sug-
gest an increase in congenital anomaly with metformin
use in pregnancy (OR of major birth defect 0.86 [95%
CI 0.18, 4.08]) [11]. However, this estimate is based on
a small sample size and, therefore, the confidence inter-
vals remain wide.
Metformin has also been extensively analysed in the
context of PCOS-associated miscarriage and pregnancy
induction. Its use appears to be neutral with regards to
miscarriage rates, although some argue that it actually
reduces rates of miscarriage [12], and it is superior
when used either alone or in combination with
clomifene for ovulation induction as compared with pla-
cebo [13].
Taken together, while there are important theoretical
concerns, metformin appears to be safe in early preg-
nancy, with no convincing evidence for an increase in
congenital malformations or miscarriage with its use.
Indeed, in the most common clinical setting of metfor-
min exposure in pregnancy, a woman with type 2 dia-
betes already on metformin in early pregnancy, the
overriding clinical issue should be that discontinuation
of use would potentially expose the patient to compli-
cations associated with poor glycaemic control. Early
clinical assessment and careful consideration of tight
control of blood glucose remain key.
Metformin use in gestational diabetesAs previously men-
tioned, for some years the use of metformin was limited
to specific geographical locations, such as Cape Town
in South Africa, but the Metformin in Gestational
Diabetes (MiG) randomised clinical trial by Rowan
et al in 2008 altered medical practice in many countries
[14]. In this study, 751 women with gestational diabetes
(GDM) were randomised to either metformin or usual
treatment with insulin therapy [14]. The safety profile
for mothers appeared to be good. Gastrointestinal side
effects led to discontinuation of metformin in 1.9% of
women and reduction in dose in 8.8%. The primary
ou t c ome i n c l u d e d a c ompo s i t e o f n e o n a t a l
hypoglycaemia (<2.6 mmol/l), respiratory distress, need
for phototherapy, 5 min Apgar score <7 or premature
birth (before 37 weeks), and was no different between
the two treatment groups, being present in 32% of both
the metformin- and insulin-treated participants.
Secondary outcomes, including birthweight, neonatal an-
thropometrics and rates of large for gestational age
(>90th percentile) were also equivalent between the
g r o up s . Howev e r , t h e r a t e s o f mo r e - s e v e r e
hypoglycaemia (<1.6 mmol/l) were reduced in the met-
formin group vs insulin therapy. It is important to note
that some 46.3% of women in the metformin group
required supplemental insulin treatment to maintain
glycaemic control. Metformin appeared to have good
patient acceptability, with 76.6% of women suggesting
that they would choose metformin in a subsequent preg-
nancy compared with 27.2% of those initially assigned
to insulin. Metformin was associated with less weight
gain between enrolment in the trial and 36 or 37 weeks
of pregnancy (0.4 ± 2.9 kg in the metformin group vs
2.0 ± 3.3 kg in the insulin group; p < 0.001) [14].
More recently, findings from a meta-analysis support-
ed the safe use of metformin as a first-line treatment for
GDM (after dietary interventions), showing that this
drug has equivalent outcomes to primary insulin treat-
ment with regards to its effects on newborns, and salu-
tary effects on maternal weight gain [15]. Furthermore,
this study suggested that metformin may have superior
outcomes to the only other oral glucose-lowering agent
used in pregnancy, glibenclamide (known as glyburide
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in the USA and Canada), although only few head-to-
head studies were used in the analysis [15]. In support
of these findings, a recent small RCT reported a similar
s a f e t y and e f f i c acy pro f i l e o f me t fo rmin vs
glibenclamide [16]. These outcomes are encouraging
as, in general, metformin use is less expensive and gen-
erally easier for patients to administer than insulin.
However, another detailed meta-analysis has also
highlighted the limited extent of the evidence base for
proper comparison of treatments [17].
Can we select which women are best suited for metformin
therapy? Women who required supplemental insulin had a
higher BMI in early pregnancy than those maintained on met-
formin (33.6 ± 8.6 kg/m2 vs 31.1 ± 7.8 kg/m2, insulin vs met-
formin), and higher baseline glucose levels (6.1 ± 1.1 mmol/l)
compared with those not requiring supplemental insulin
(5.3 ± 0.8 mmol/l) [14]. This is broadly similar for other
glucose-lowering agents, such as glibenclamide, the failure of
which is more likely when initial fasting glucose is high
(>6.4mmol/l) [18], and these observationsmake sense, a priori,
as women with higher glucose levels are likely to have more
severe disease. Similarly, women presenting with GDM earlier
in pregnancy are more likely to require insulin and may be
considered less suitable for oral agents.
Metformin use in type 2 diabetes The familiarity of metfor-
min in general diabetes practice and the recent encouraging
results from the MiG trial have led to speculation as to its
possible uses in women with type 2 diabetes in pregnancy. It
is important to note, however, that the evidence base is very
small.
Given the insulin resistance of pregnancy, it is likely
that most women with type 2 diabetes before pregnancy
will require treatment with insulin during their pregnan-
cy, simply to maintain glycaemic control. Is there a role
then for metformin as an insulin-sparing agent? There
are only a few observational studies on the use of met-
formin in type 2 diabetes in pregnancy; in 2000,
Hellmuth et al reported use of metformin in 50 women
in Denmark, 19 of whom had type 2 diabetes [19]. In
this retrospective study examining the historical practice
with oral glucose-lowering agents between 1966 and
1984, an increase in pre-eclampsia and perinatal mortal-
ity was noted with metformin use compared with treat-
ment with sulfonylureas or insulin [19]. Levitt and col-
leagues reported observational data from South Africa;
in their extensive study, women with pregestational type
2 diabetes were treated with insulin or oral glucose-
lowering agents before and during pregnancy. Notably,
this was also not a randomised study but reflected local
practice. Critically, they observed a very high rate of
perinatal mortality (125 events per 1000 births) in the
group treated with oral glucose-lowering medication
(predominantly metformin and glibenclamide) through-
out pregnancy compared with women who converted
from oral glucose-lowering agents to insulin (28 events
per 1000 births) or women who converted from diet to
insulin or remained on insulin during pregnancy (33
events per 1000 births) [8]. In contrast, in 2006
Hughes and Rowan reported observational data on the
use of metformin in type 2 diabetes in the New Zealand
population; they reported no increase in adverse preg-
nancy outcomes despite a worse risk-factor profile at
baseline compared with women not taking metformin
[20].
As detailed above, the evidence base for metformin
use in pregestational type 2 diabetes is not strong, as
trials were not randomised and liable to selection bias.
Nevertheless, it would appear inadvisable to consider
metformin as a sole agent for the management of wom-
en with type 2 diabetes in pregnancy. As a separate
issue, there is a potential for use of metformin as an
insulin-sparing agent with potential benefits on weight
gain in pregnancy and, more, speculatively on
glycaemic control. However, there is clearly not enough
evidence at this time to recommend such use, with an
obvious need for randomised evidence to elucidate the
benefits, if any, of metformin as an additional agent for
the management of type 2 diabetes in pregnancy.
Currently ongoing randomised trials in this area will
inform the debate in the future [21].
Does metformin have long-term effects on the child
after treatment in utero?
As detailed above, there is not strong evidence of safety
problems for metformin during pregnancy. Therefore,
most of the lingering safety concerns revolve around
potential long-term effects of metformin exposure in
utero. At the time of writing, randomised evidence aris-
ing from metformin exposure during pregnancy, to treat
GDM, extends to only 2 years, although longer-term
studies are expected. In MiG: the offspring follow-up
(MiG TOFU), children exposed to metformin in utero
were shown to have no difference in total fat mass and
body fat percentage, as assessed by bioimpedance, al-
though children did have slightly larger mid-upper arm
circumferences, subscapular and bicep skinfolds [22].
There were no differences in blood pressure [23].
Follow-up of a Finnish RCT found that children ex-
posed to metformin in pregnancy were significantly
heavier at the age of 12 months, and taller and heavier
(12.0 vs 11.3 kg) at 18 months, although the study was
small, with a total of 97 children. The mean ponderal
index (PI) did not differ significantly and there were no
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differences in motor, social and linguistic development
evaluated at the age of 18 months [24]. Follow-up of a
small RCT in women with PCOS suggested no differ-
ence in BMI at 8 years, but only included 25 children
[25]. The limitations of size of study and length of
follow-up in the available studies are noted in a recent
review [26].
Does recent basic science explain how use
of metformin in pregnancy can affect the embryo
or fetus?
Is there malformation risk to the embryo? As noted
above, increased embryo AMPK activity mediates some
of the adverse effects of maternal diabetes on congenital
malformations in mouse embryos, raising the concern
that metformin stimulation of embryo AMPK activity
could counteract the beneficial effects of lowering ma-
ternal blood glucose levels [27]. In addition, the effects
of metformin on one-carbon pathways, which are similar
to the effects of anti-folate chemotherapeutic drugs [28],
and the essential role of folate in preventing neural tube
(and other) malformations [29] raises further concern as
to whether metformin might increase embryo malforma-
tion risk. However, at doses that stimulated maternal
liver AMPK activity, metformin did not stimulate em-
bryo AMPK activity or increase congenital anomalies
[10]. Metformin did, however, stimulate AMPK activity
and inhibit expression of a gene associated with congen-
ital malformations in mouse embryonic stem cells (ESC)
that were used as an in vitro model to study diabetic
embryopathy [10]. Interestingly, the difference in met-
formin susceptibility between mouse embryos and
mouse ESC was related to differential expression of
metformin transporters [10]. Metformin is transported
by organic cation transporters (OCTs) the normal func-
tion of which is to take up and extrude organic cations,
such as thiamine, choline, neurotransmitters, creatinine,
carnitine, guanidine and steroid hormones [30]. Slc47a1
and Slc22a3 mRNA, encoding the metformin trans-
porters multidrug toxin and extrusion (MATE) 1 and
OCT3, respectively, were expressed at negligible or un-
detectable levels in embryos, but Slc22a3 was expressed
by ESC, albeit at much lower levels than by maternal
liver [10]. The differences in metformin transporter ex-
pression and metformin responsiveness between normal
mouse embryos and ESC could be a result of metabolic
differences between ESC lines in culture and the normal
embryo in vivo. It should be noted that the ESC line
that was used to study potential teratogenic effects of
metformin [10] does not exhibit the responsiveness to
high glucose exposure and the high rates of glycolysis
relative to oxidative phosphorylation of normal embryos
or of ESC derived in physiological glucose media [31].
While conventional stem cell (embryonic and induced
pluripotent) lines exhibit fewer, and less mature, mito-
chondria compared with more differentiated cells, and
high rates of glycolysis relative to oxidative phosphory-
lation are essential for induction of pluripotency from
differentiated cells [32–34], conventional ESCs may be
more dependent on mitochondrial metabolism (and less
dependent on glycolysis) than the normal mouse embryo
in vivo. One can speculate that the endogenous solutes
taken up by metformin transporters (OCTs) have a func-
tion in mitochondrial metabolism, such that metformin
transporters would not be expressed by cells that are
highly dependent on glycolysis, but would occur upon
maturation of mitochondrial respiration (Fig. 1).
Consistent with this, metformin and phenformin compet-
itively inhibit thiamine uptake by hepatocytes, causing
inhibition of the tricarboxylic acid cycle [35]. Whether
the human embryo also lacks metformin transporter ex-
pression and metformin responsiveness is not known.
However, preimplantation human embryos have low mi-
tochondrial content and are dependent on anaerobic me-
tabolism [32], suggesting that early human embryos
may be unresponsive to metformin.
Are there metabolic programming effects on the fetus?
Compared to the embryo, fetal and placental cells are
more differentiated and more dependent on oxidative me-
tabolism and mitochondrial activity. Metformin inhibits
complex I of the respiratory chain, leading to an in-
creased AMP:ATP ratio that stimulates AMPK activity
[36–38]. AMPK regulates several processes including
gene expression and mechanistic target of rapamycin
(mTOR)-induced effects on protein synthesis [27,
39–41]. In addition, there are separated, but nonredundant
mitochondrial and cytosolic pathways that generate one-
carbon intermediates that can be inhibited by metformin,
mimicking the ‘methyl folate trap’ that can occur during
vitamin B12 deficiency [28, 42, 43]. This can lead to
methionine deprivation, decreased glutathione (reduced,
oxidised disulphide and trisulphide forms), increased ho-
mocysteine, and decreased de novo synthesis of purines
and pyrimidines [28, 42]. In addition, inhibition of one-
c a r b o n me t a b o l i sm d e c r e a s e s l e v e l s o f S -
adenosylmethionine (SAM) and increases levels of S-
adenosylhomocysteine (SAH), which could have epigenet-
ic effects on gene expression because of reduced DNA
and histone methylation. Further, a recent study using the
round worm Caenorhabditis elegans showed that metfor-
min inhibits cell growth and promotes longevity through
inhibition of mitochondrial respiration, leading to reduced
transit of the Ras-related GTP-binding protein C (RagC)
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GTPase through the nuclear pore complex (NPC) and
inhibition of mTOR signalling [44]. This pathway is high-
ly conserved throughout evolution and may explain the
anti-cancer effect of metformin, because the same metfor-
min response reduces viability of melanoma and pancre-
atic cancer cells [44]. These observations raise the ques-
tion: since metformin appears to use some of the same
mechanisms as nutrient restriction to promote longevity
and inhibit cancer growth [42, 45], and dietary restriction
(and vitamin B12 deprivation) can programme increased
cardiometabolic risk in the offspring [46, 47], could met-
formin exert long-term negative effects on cardiometabolic
risk in the offspring?
In order for metformin to affect fetal or placental physiol-
ogy and development, the cells in these tissues must be able to
take up metformin. Furthermore, because metformin is posi-
tively charged at neutral pH, there must be a strong mitochon-
drial membrane potential for it to enter the mitochondrial ma-
trix [48]. Human placentas express several OCT isoforms
(OCT1, OCT2, OCT3, and MATE1 and MATE2) [49], and
metformin may indirectly affect fetal development, for exam-
ple, through altered nutrient delivery or placental growth; al-
though, this requires further investigation. Whether fetal tis-
sues express OCTs has not been carefully studied. It should be
noted that metformin may not have lasting effects on organs
whose growth and repopulation depends on progenitor cells,
unless those progenitor cells take up and are metabolically or
epigenetically altered by metformin. Yet, in the case of the
liver, where it appears that hepatocytes are derived primarily
from pre-existing hepatocytes rather than stem cells [50, 51],
the epigenetic effects of metformin could have long-term out-
comes if chromatin modifications are passed onto daughter
cells.
International use of metformin
Metformin use appears quite varied between countries. In
New Zealand, guidelines published by the Ministry of
Health in 2014, after extensive review of the evidence, recom-
mended ‘where women who have gestational diabetes and
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and must, therefore, be interpreted with caution.
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of severe hypoglycaemia (< 1.6 mmol/l) vs other 
agents; reduced pregnancy weight gain vs insulin; 
superior to glibenclamide for glucose control; more 
likely to fail in women with higher baseline glucose 
or presenting with diabetes earlier in pregnancy. 
Similar effects on newborn health vs insulin.
Type 2 diabetes Only observational evidence.
Long-term effects in offspring Equivocal 
evidence for changes in body composition; no differ-
ences in BP; no differences in motor, social and 
linguistic development at 18 months. 
Fetal effects No convincing evidence for increase 
in congenital malformations or miscarriage; long-
term effects on health or metabolism during adult-
hood not known.
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poor glycaemic control (above treatment targets) in spite of
dietary and lifestyle interventions, offer oral hypoglycaemics
(metformin or glibenclamide) and/or insulin therapy’ [52]. In
Scotland, UK, the Scottish Intercollegiate Guidelines Network
(SIGN publication no. 116; 2010) suggested that ‘metformin
or glibenclamide may be considered as initial pharmacologi-
cal, glucose-lowering treatment in women with gestational
diabetes’ [53].
In contrast, the most recent ADA standard of medical care
notes that insulin is the first-line agent recommended for treat-
ment of GDM in the USA [54]. Metformin was noted to have
randomised evidence for safety and efficacy, but the lack of
long-term safety data for offspring was also noted. The US
Food and Drug Administration (FDA) places metformin in
category B: ‘Animal reproduction studies have failed to dem-
onstrate a risk to the fetus, and there are no adequate and well-
controlled studies in pregnant women’ [54].
In England and Wales (UK), the National Institute for
Health and Care Excellence (NICE) recommends that clini-
cians ‘offer metformin to women with gestational diabetes if
blood glucose targets are not met using changes in diet and
exercise within 1–2 weeks’. However, at the same time, these
recommendations note that the summary of product character-
istics for metformin suggests that it should not be used in
pregnancy but, instead, insulin should be used [55].
Australian guidelines issued by the Royal Australian
College of General Practitioners note that ‘metformin has
been used internationally as initial glucose-lowering treatment
in women with GDM. However, it has not been approved for
this use in Australia for this indication. Lifestyle and insulin
therapy remain the mainstay of therapy’ [56].
Conclusions
International use of metformin in pregnancy has increased
greatly in the last decade. The drug is familiar, relatively in-
expensive and easy to administer, and is associated with clear
benefits as a treatment of hyperglycaemia in pregnancy. For
many clinicians, a major concern is the stopping of metformin
early in pregestational type 2 diabetes, without adequate re-
placement, potentially worsening hyperglycaemia. At the
same time, as a community, clinicians treating women with
diabetes in pregnancy are appropriately, very sensitive to the
potential for long-term adverse outcomes. At the time of writ-
ing, there certainly do not appear to be clear data suggesting a
long-term problem with metformin use, but some clinicians
will want to await further data. One troubling aspect of this is
that, given the relatively small size of funded studies, difficul-
ty of maintaining cohorts in the longer term, and the potential
for high attrition rates, we may never have absolutely clear
evidence for this. On its sixtieth anniversary then, perhaps,
metformin stands as an exemplar of how research in the
management of medical conditions in pregnancy must devel-
op. Those on either side of the debate about its use will agree
that better data should have been available earlier and hope
that the debate will be able to move on prior to metformin’s
next significant anniversary.
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